Small cell lung cancer · 6 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Durvalumab monotherapy Variant #01 | — | R 61 460 | 14d | 16.6 mo | 55.9 mo | 26 | R 1 597 971 PFS proxy | 2 |
Cisplatin and Irinotecan (IC) Variant #01 | — | R 1 795 | 21d | — | ~10.2 mo | ~5 | ~R 8 977 PFS proxy · indirect | 3 |
Whole brain irradiation N/A - radiation | — | — | 21d | — | 6.7 mo | — | — | 1 |
Observation Partial | — | — | — | — | 16.4 mo | — | — | 1 |
Placebo Partial | — | — | — | 9.2 mo | 33.4 mo | — | — | 2 |
Radiation therapy N/A - radiation | — | — | 49d | ~5.1 mo | ~12.0 mo | — | — | 1 |
6 of 6 regimens shown